全文获取类型
收费全文 | 655篇 |
免费 | 48篇 |
国内免费 | 3篇 |
专业分类
耳鼻咽喉 | 5篇 |
儿科学 | 14篇 |
妇产科学 | 9篇 |
基础医学 | 47篇 |
口腔科学 | 10篇 |
临床医学 | 64篇 |
内科学 | 145篇 |
皮肤病学 | 3篇 |
神经病学 | 21篇 |
特种医学 | 28篇 |
外科学 | 83篇 |
综合类 | 6篇 |
一般理论 | 1篇 |
预防医学 | 16篇 |
眼科学 | 15篇 |
药学 | 32篇 |
肿瘤学 | 207篇 |
出版年
2023年 | 7篇 |
2022年 | 13篇 |
2021年 | 20篇 |
2020年 | 10篇 |
2019年 | 15篇 |
2018年 | 32篇 |
2017年 | 17篇 |
2016年 | 10篇 |
2015年 | 15篇 |
2014年 | 19篇 |
2013年 | 27篇 |
2012年 | 42篇 |
2011年 | 35篇 |
2010年 | 24篇 |
2009年 | 26篇 |
2008年 | 62篇 |
2007年 | 45篇 |
2006年 | 58篇 |
2005年 | 63篇 |
2004年 | 37篇 |
2003年 | 23篇 |
2002年 | 27篇 |
2001年 | 1篇 |
2000年 | 6篇 |
1999年 | 5篇 |
1998年 | 2篇 |
1997年 | 3篇 |
1996年 | 6篇 |
1995年 | 4篇 |
1994年 | 6篇 |
1993年 | 3篇 |
1992年 | 4篇 |
1991年 | 8篇 |
1990年 | 4篇 |
1989年 | 5篇 |
1988年 | 4篇 |
1987年 | 3篇 |
1986年 | 6篇 |
1983年 | 1篇 |
1981年 | 3篇 |
1979年 | 1篇 |
1977年 | 1篇 |
1975年 | 1篇 |
1974年 | 2篇 |
排序方式: 共有706条查询结果,搜索用时 0 毫秒
61.
62.
63.
64.
65.
66.
67.
Gastric cancer is the fourth most common malignancy worldwide with Japan, Korea, Taiwan, China, Mongolia and many countries in South America and eastern Europe, as well as parts of the Middle East, contributing to the majority of cases. In the USA, it was estimated that approximately 10,620 deaths would be caused by gastric cancer in 2010. Gastric cancer is often diagnosed in its advanced stages. Current first-line treatment for advanced gastric cancer (AGC) using triplet combination chemotherapy containing a platinum-based compound, a fluoropyrimidine with an anthracycline (frequently added in Europe) or a taxane (more often used in the USA and elsewhere) has resulted in higher response rates and modest improvement in overall survival compared with doublet combinations. However, triplet combinations can be associated with increased toxicity compared with the doublets and patient selection becomes important. A desirable research strategy is to improve outcomes of patients with AGC by identifying treatments that are effective, convenient and safe. The interest in oral agents compared with intravenous agents is mounting. One oral fluoropyrimidine, S-1, is novel as it combines tegafur, 5-chloro-2,4-dihydroxypyridine and potassium oxonate. S-1 is approved in Japan, China, Taiwan, Korea and Singapore for the treatment of patients with gastric cancer, and more recently has been approved in 27 European countries to treat AGC. Initial clinical trials in the USA and Europe observed diarrhea as the dose-limiting toxicity; however, initial Japanese studies reported myelosuppression as the dose-limiting toxicity. The differing dose tolerance in these two populations is likely due to polymorphisms in the CYP2A6 gene. Based on our review of Phase II and III studies, we conclude that S-1 is a convenient oral fluoropyrimidine that provides safety advantage over intravenous fluorouracil without compromising efficacy against AGC. 相似文献
68.
69.
Approximately one million people in the US have permanent pacemakers. These patients are usually seen in general practice and referred to a cardiologist. Therefore, it is important for the internists and hospitalists to be aware of the indications and complications of cardiac pacing. 相似文献
70.